DCOY Key Statistics, Chart & Performance
The current stock price of DCOY is 0.8638 USD.
DCOY Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DCOY.
DCOY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to DCOY. The financial health of DCOY is average, but there are quite some concerns on its profitability.
DCOY Financial Highlights
Over the last trailing twelve months DCOY reported a non-GAAP Earnings per Share(EPS) of -39.18. The EPS increased by 68.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.08% | ||
| ROE | -117.81% | ||
| Debt/Equity | 0 |
DCOY Forecast & Estimates
DCOY Ownership
About DCOY
Company Profile
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Company Info
DECOY THERAPEUTICS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS US
Employees: 2
Phone: 13467720346
DECOY THERAPEUTICS INC / DCOY FAQ
What does DCOY do?
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Can you provide the latest stock price for DECOY THERAPEUTICS INC?
The current stock price of DCOY is 0.8638 USD. The price increased by 4.07% in the last trading session.
Does DECOY THERAPEUTICS INC pay dividends?
DCOY does not pay a dividend.
How is the ChartMill rating for DECOY THERAPEUTICS INC?
DCOY has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the employee count for DCOY stock?
DECOY THERAPEUTICS INC (DCOY) currently has 2 employees.
What is DECOY THERAPEUTICS INC worth?
DECOY THERAPEUTICS INC (DCOY) has a market capitalization of 5.06M USD. This makes DCOY a Nano Cap stock.
Can you provide the ownership details for DCOY stock?
You can find the ownership structure of DECOY THERAPEUTICS INC (DCOY) on the Ownership tab.